Skip to main content
. 2019 Jul 12;8(7):1027. doi: 10.3390/jcm8071027

Figure 2.

Figure 2

Effects of a selective leptin receptor antagonist (LDFI) on exosome release in breast cancer cells. (A) Representative images of transmission electron microscopy (TEM) showing fields of Multivesicular bodies (MVBs) in MCF-7 and MDA-MB-231 breast cancer cells treated with vehicle (-) Leptin (Lep, 500 ng/mL) alone or in combination with the leptin antagonist (LDFI, 1 μM) for 48 h. Scale bar 1 μm. The histograms represent the mean ± S.D. of the MVB numbers in more than 15 fields per condition. (B) Representative size distribution profiles of exosomes (Exo), measured by nanoparticle tracking analysis, from conditioned media of MCF-7 and MDA-MB-231 breast cancer cells treated with vehicle (-) or Leptin (Lep, 500 ng/mL) alone or in combination with the leptin antagonist (LDFI, 1 μM) for 48 h. The histograms represent the mean ± S.D. of exosome concentration (particles/mL/106 cells) of two different experiments. (C) Concentration of exosomes released from MCF-7 and MDA-MB-231 breast cancer cells treated with vehicle (-), Leptin (Lep, 500 ng/mL) alone or in combination with the leptin antagonist (LDFI, 1 μM) for 48 h measured by acetylcholinesterase activity assay (AchE Activity). * p < 0.05, *** p < 0.001.